Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: April 3, 2025
Event: Regulation FD Disclosure regarding a scientific poster presentation.
Key Event Details
On April 3, 2025, the Company presented a poster at the annual International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders in Vienna, Austria. The presentation details patient demographics and biomarker status at enrollment for the Company's MINDFul Phase II blinded, randomized trial in patients with early Alzheimer's disease and biomarkers of inflammation.
Financial Metrics
This filing is a Current Report (Form 8-K) focused on a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves solely to disclose the scientific presentation mentioned above.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the dissemination of clinical trial data regarding the MINDFul Phase II study.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. It shall not be incorporated by reference into any other filing under the Securities Act or Exchange Act.
- Risks/Contingencies: No specific risks or contingencies are detailed in this text beyond the standard regulatory disclaimers regarding the status of the furnished information.
Investor Verification Checklist
- Verify the full content of the "Poster Presentation" (Exhibit 99.1) to understand the specific demographics and biomarker data released.
- Confirm the current status and timeline of the MINDFul Phase II trial for early Alzheimer's disease.
- Review subsequent filings for any financial updates or clinical trial results that may follow this initial data disclosure.